Akums Drugs and Pharmaceuticals IPO
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
| Issue Open | 30-07-2024 |
| Issue Close | 01-08-2024 |
| Allotment Date | 02-08-2024 |
| Listing Date | 06-08-2024 |
| IPO Price Band | ₹646 to ₹679 |
| Minimum Share Bid | 22 |
| Minimum Investment Amount | ₹14938 |
| Total Issue Size | 2,73,45,162 shares (up to ₹1,856.736 Cr) |
| Fresh Issue | 1,00,14,727 shares (up to ₹680 Cr) |
| Offer For Sale | 1,73,30,435 shares (up to ₹1,176.737 Cr) |
| Face Value | ₹2 Per Share |
| Employee Discount | ₹64 per share |
| Qualified Institutional Buyer [QIB] | 75% |
| High Networth Individual [HNI] | 15% |
| Retail Individual Investor [RII] | 10% |
| Listed on | NSE BSE |
| Listing Date | 06-08-2024 |
| BSE Code | - |
| NSE Code | AKUMS |
| ISIN Code | - |
| IPO Price | ₹ 679 |
| Lot Size | 22 |
| Expected Listing Price | - |
| Book Profit | - |
| Stop Loss | - |
Can't fetch the data
| Financial Year | Total Asset | Total Revenue | Total Expenses | Profit |
|---|---|---|---|---|
| FY-2021 | - | - | - | - |
| FY-2022 | 3,069.05 | 3,694.52 | 3,874.94 | -250.87 |
| FY-2023 | 3,266.53 | 3,700.93 | 3,475.92 | 97.82 |
| FY-2024 | 3,516.37 | 4,212.21 | 4,231.45 | 0.79 |
| Earnings Per Share [EPS] | ₹ -0.28 |
| Price/Earnings [P/E] Ratio | - |
| Return on Net Worth [RoNW] | -0.57 % |
| Net Asset Value [NAV] | ₹ 49.59 Per Share |
| Application | Lot Size | Shares | Total Amount |
|---|---|---|---|
| Retail Min | 1 | 22 | ₹ 14,938 |
| Small HNI | 14 | 308 | ₹ 2,09,132 |
| Big HNI | 67 | 1,474 | ₹ 10,00,846 |
Before applying to any IPO, please thoroughly check the company's fundamentals and financial condition.
www.liveipo.in or its producers are not responsible for any profits or losses. IPO applications are made at your own risk.
We do not buy or sell any IPO applications related to IPO Gray Market Premium. We only provide information.
Do not subscribe to any IPO solely based on Gray Market Premium prices, as they can fluctuate at any time.
We are not Financial Advisors. Please consult your financial advisor before investing or trading.
All updates, posts, and discussions are for educational and learning purposes only.
Our disclaimers and terms & conditions apply to all viewers and members of LiveIPO Groups or Channels.
All content is based on research and case studies from various sources including books, media, and internet.
LiveIPO Group, Channel, Website or App does not provide tips, recommendations, or investment advice.
Group Admins or Owners are not responsible for any financial losses.
We do not publish any stock market magazines.
We are not SEBI registered analysts.
Stock Market investments are subject to market risk.
The content provided in this application is for educational and informational purposes only. It does not constitute financial advice to buy or sell securities, invest in IPOs, or make any other financial decisions. All information reflects data and market perceptions as of the publication date. We are not SEBI-registered analysts. Please consult a qualified financial advisor before making investment decisions. By using this app, you agree to our terms and conditions.
© 2024 LiveIPO. All rights reserved.